SPC Logo

VAQTA Paediatric

Last Updated on eMC 28-Oct-2013 View changes  | Sanofi Pasteur MSD Limited Contact details

1. Name of the medicinal product

VAQTA® Paediatric, suspension for injection

Hepatitis A Vaccine, inactivated, adsorbed.

For children and adolescents.

2. Qualitative and quantitative composition

One dose (0.5mL) contains:

Hepatitis A virus (strain CR 326F) (inactivated) 1,2 …………………25 U 3

1 Produced on human diploid (MRC–5) fibroblast cells.

2 Adsorbed on amorphous aluminium hydroxyphosphate sulphate ( 0.225 mg Al 3+).

3 Units measured according to the in-house method of the manufacturer-Merck Sharp & Dohme Corp.

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

Suspension for injection in a prefilled syringe or vial.

4. Clinical particulars
4.1 Therapeutic indications

VAQTA Paediatric is indicated for active pre-exposure prophylaxis against disease caused by hepatitis A virus. VAQTA Paediatric is recommended for healthy individuals from 12 months of age to 17 years of age who are at risk of contracting or spreading infection or who are at risk of life-threatening disease if infected (e.g., hepatitis C with diagnosed liver disease).

The use of VAQTA Paediatric should be based on official recommendations.

For optimal antibody response, primary immunisation should be given at least 2, preferably 4, weeks prior to expected exposure to hepatitis A virus.

VAQTA Paediatric will not prevent hepatitis caused by infectious agents other than hepatitis A virus.

4.2 Posology and method of administration

Posology

The vaccination series consists of one primary dose and one booster dose given according to the following schedule:

Primary dose:

Children and adolescents aged 12 months to 17 years of age should receive a single 0.5 mL (25U) dose of vaccine at an elected date.

Safety and effectiveness in infants <12 months of age have not been established.

Booster dose:

Individuals who received a primary dose at 12 months to 17 years of age should receive a booster dose of 0.5 mL (25U) 6 to 18 months after the first dose.

Hepatitis A virus (HAV) antibodies persist for at least 10 years after the second dose (i.e. booster). Based on mathematic modeling duration of antibody persistence is predicted for at least 25 years (see section 5.1).

Interchangeability of the booster dose

A booster dose of VAQTA Paediatric may be given at 6 to 12 months following the initial dose of other inactivated hepatitis A vaccines as shown by data for adults, 18 to 83 years of age; no such data are available for VAQTA (25U/0.5 mL) presentation.

Method of administration

VAQTA Paediatric should be injected INTRAMUSCULARLY. The deltoid muscle is the preferred site for injection. The anterolateral thigh region may be used in infants if the deltoid muscle is not sufficiently developed. The vaccine should not be administered subcutaneously or intradermally since administration by these routes may result in a less than optimal antibody response.

For individuals with bleeding disorders who are at risk of haemorrhage following intramuscular injection (e.g., haemophiliacs) other measures can be taken such as intramuscular administration of the vaccine after anti-haemophilia or other similar therapy, or applying pressure. This vaccine may be administered subcutaneously to these subjects.

VAQTA Paediatric must not be administered into a blood vessel.

4.3 Contraindications

Hypersensitivity to any component of the vaccine.

Vaccination should be delayed in subjects with current severe febrile infections.

4.4 Special warnings and precautions for use

Individuals who develop symptoms suggestive of hypersensitivity after an injection of VAQTA Paediatric should not receive further injections of the vaccine (see section 4.3 Contraindications).

Use caution when vaccinating latex-sensitive individuals since the syringe plunger stopper and tip cap contain dry natural latex rubber that may cause allergic reactions.

Qualitative testing for antibodies to hepatitis A prior to immunisation should be considered based on the probability of previous hepatitis A virus infection in patients who grew up in areas of high endemicity, and/or with a history of jaundice.

VAQTA Paediatric does not cause immediate protection against hepatitis A, and there may be a period of 2 to 4 weeks before antibody becomes detectable.

VAQTA Paediatric will not prevent hepatitis caused by infectious agents other than hepatitis A virus. Because of the long incubation period (approximately 20 to 50 days) for hepatitis A, it is possible for unrecognised hepatitis A infection to be present at the time the vaccine is given. The vaccine may not prevent hepatitis A in such individuals.

As with any vaccine, adequate treatment provisions, including epinephrine (adrenaline), should be available for immediate use should an anaphylactic or anaphylactoid reaction occur.

As with any vaccine, vaccination with VAQTA Paediatric may not result in a protective response in all susceptible vaccinees.

This vaccine may contain traces of neomycin and formaldehyde which are used during the manufacturing process.

4.5 Interaction with other medicinal products and other forms of interaction

If VAQTA Paediatric is used in individuals with malignancies or those receiving immunosuppressive therapy or who are otherwise immunocompromised, the expected immune response may not be obtained.

Known or presumed exposure to HAV/travel to endemic areas

Use with immune globulin

For individuals requiring either post-exposure prophylaxis or combined immediate and longer term protection (e.g., travelers departing on short notice to endemic areas), in countries where IG is available VAQTA Paediatric may be administered concomitantly with IG using separate sites and syringes. Although the antibody titre obtained is likely to be lower than when the vaccine is given alone. The clinical relevance of this observation has not been established.

VAQTA Paediatric Concomitant Use With Other Vaccines

Hepatitis A response has been shown to be similar when VAQTA Paediatric was given alone or concomitantly with measles, mumps, rubella, varicella, pneumococcal 7-valent conjugate, inactivated polio, diphtheria toxoid, tetanus toxoid, acellular pertussis, or Haemophilus influenzae b vaccine. Responses to measles, mumps, rubella, varicella, pneumococcal 7-valent conjugate, inactivated polio, diphtheria toxoid, tetanus toxoid, acellular pertussis, and Haemophilus influenzae b vaccine were not affected by concomitant administration with VAQTA Paediatric. Studies in adults 18 to 54 years of age have shown that VAQTA may be administered concomitantly with yellow fever and polysaccharide typhoid vaccines.

VAQTA Paediatric must not be mixed with other vaccines in the same syringe. When concurrent administration is necessary, different injection sites and separate syringes must be used for each vaccine.

4.6 Pregnancy and lactation

Animal reproduction studies have not been conducted with VAQTA Paediatric. It is not known whether VAQTA Paediatric can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity. VAQTA Paediatric is not recommended in pregnancy unless there is a high risk of hepatitis A infection, and the attending physician judges that the possible benefits of vaccination outweigh the risks to the foetus.

It is not known whether VAQTA Paediatric is excreted in human milk, and the effect on breastfed infants following administration of VAQTA Paediatric to mothers has not been studied. Hence, VAQTA Paediatric should be used with caution in women who are breastfeeding.

4.7 Effects on ability to drive and use machines

There are no data to suggest that VAQTA Paediatric affects the ability to drive or operate machinery.

4.8 Undesirable effects

Clinical Studies

Children 12 Months Through 23 Months of Age

In 5 combined clinical trials, 4374 children 12 through 23 months of age received one or two 25U doses of VAQTA Paediatric. Out of the 4374 children who received VAQTA Paediatric, 3885 (88.8%) children received 2 doses of VAQTA Paediatric and 1250 (28.6%) children received VAQTA Paediatric concomitantly with other vaccines. Children were followed for elevated temperature and injection-site adverse reactions during a 5-day period postvaccination and systemic adverse events including fever during a 14-day period postvaccination.

In three of the five protocols which specifically prompted for injection-site erythema, pain/tenderness, and swelling daily for Day 1 through Day 5 postvaccination, the most frequently reported injection-site adverse reaction after any dose of VAQTA Paediatric was injection-site pain/tenderness.

The most common systemic adverse events among recipients of VAQTA Paediatric alone were fever and irritability. The data from the five protocols were combined as similar methods for collecting systemic adverse events were used.

The adverse events that were reported as vaccine related when VAQTA Paediatric was administered alone are listed below in decreasing order of frequency within each system organ classification.

[Very Common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very Rare (< 1/10,000); Not Known (cannot be estimated from the available data) ]

Immune system disorders:

Rare: multiple allergies.

Metabolism and nutrition disorders:

Uncommon: decreased appetite; anorexia.

Rare: dehydration.

Psychiatric disorders:

Uncommon: insomnia; restlessness.

Rare: agitation; nervousness; phobia; screaming; sleep disorder.

Nervous system disorders:

Uncommon: somnolence; crying; lethargy; hypersomnia; poor quality sleep.

Rare: dizziness; headache; ataxia.

Eye disorders:

Rare: eyelid margin crusting.

Respiratory, thoracic and mediastinal disorders:

Uncommon: rhinorrhoea; cough; nasal congestion.

Rare: respiratory tract congestion; sneezing; asthma; allergic rhinitis; oropharyngeal pain.

Gastrointestinal disorders:

Common: diarrhoea.

Uncommon: vomiting.

Rare: flatulence; abdominal distension; upper abdominal pain; faeces discoloured; frequent bowel movements; nausea; stomach discomfort; constipation; eructation; infantile spitting up.

Skin and subcutaneous tissue disorders:

Uncommon: rash; dermatitis diaper.

Rare: urticaria; cold sweat; eczema; generalised erythema; papular rash; blister; erythema; generalised rash; heat rash; hyperhydrosis; skin warm.

Musculoskeletal and connective tissue disorders:

Rare: synovitis.

General disorders and administrative site conditions:

Very Common: injection-site pain/tenderness; injection-site erythema.

Common: injection-site swelling; fever; irritability; injection-site warmth; injection-site bruising.

Uncommon: injection-site haematoma; injection-site nodule; malaise; injection-site rash.

Rare: pain; injection-site haemorrhage; injection-site pruritus; discomfort; fatigue; gait disturbance; injection-site discolouration; injection-site papule; injection-site urticaria; feeling hot.

Children/Adolescents (2 Through 17 Years of Age)

In clinical trials with 2595 healthy children (≥2 years of age) and adolescents who received one or more doses of hepatitis A vaccine, subjects were followed for elevated temperature and local reactions during a 5-day period postvaccination and systemic adverse experiences including fever during a 14-day period postvaccination. Injection-site reactions, generally mild and transient, were the most frequently reported adverse experiences.

Adverse experiences reported as vaccine related are listed below in decreasing order of frequency within each system organ classification.

[Very Common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very Rare (< 1/10,000); Not Known (cannot be estimated from the available data)]

Metabolism and nutrition disorders:

Rare: anorexia.

Psychiatric disorders:

Uncommon: irritability.

Rare: nervousness.

Nervous system disorders:

Common: headache.

Uncommon: dizziness.

Rare: somnolence; paraesthesia.

Ear and labyrinth disorders:

Rare: ear pain.

Vascular disorders:

Rare: flushing.

Respiratory, thoracic and mediastinal disorders:

Rare: nasal congestion; cough; rhinorrhoea.

Gastrointestinal disorders:

Uncommon: abdominal pain; vomiting; diarrhoea; nausea.

Skin and subcutaneous tissue disorders:

Uncommon: rash; pruritus.

Rare: urticaria; sweating.

Musculoskeletal, connective tissue and bone disorders:

Uncommon: arm pain (in the injected limb); arthralgia; myalgia.

Rare: stiffness.

General disorders and administrative site conditions:

Very common: injection-site pain and tenderness.

Common: injection-site warmth, erythema and swelling; fever; injection-site ecchymosis.

Uncommon: asthenia/fatigue; injection-site pruritus and pain/soreness.

Rare: injection-site induration; flu-like illness; chest pain; pain; warm sensation; injection-site scab; stiffness/tightness and stinging.

As with all vaccines, allergic reactions, in rare cases leading to shock, may occur (see section 4.4 Special warnings and precautions for use).

Marketed experience

The following additional adverse reactions have been reported with use of the marketed vaccine.

Nervous system disorders

Very rarely, Guillain-Barré syndrome.

Blood and lymphatic system disorders

Very rarely, thrombocytopenia.

Post-marketing Safety Study

In a post-marketing safety study, a total of 12,523 individuals 2 through 17 years of age received 1 or 2 doses of VAQTA Paediatric. There was no serious, vaccine-related, adverse event identified. There was no nonserious, vaccine-related, adverse event resulting in outpatient visits.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

There are no data with regard to overdose.

5. Pharmacological properties

Pharmacotherapeutic group: viral vaccines, ATC code: J07BC

5.1 Pharmacodynamic properties

VAQTA Paediatric is derived from hepatitis A virus that has been cultured in human MRC-5 diploid fibroblasts. It contains inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, highly purified, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulphate.

Efficacy of VAQTA Paediatric: The Monroe Clinical Study

Clinical studies showed that the seroconversion rate in children TILDE OPERATOR (8764)12 months of age was 96% within 6 weeks after the recommended primary dose and that the seroconversion rate was 97% in children (≥2 years of age) and adolescents within 4 weeks after the recommended primary dose. The onset of seroconversion following a single dose of VAQTA Paediatric was shown to parallel the onset of protection against clinical hepatitis A disease. Protective efficacy has been demonstrated after a single dose of VAQTA Paediatric in 1037 children and adolescents 2 to 16 years of age in a US community with recurrent outbreaks of hepatitis A (The Monroe Efficacy Study). Seroconversion was achieved in more than 99% of vaccine recipients within 4 weeks of the vaccination. The pre-exposure protective efficacy of a single dose of VAQTA Paediatric was observed to be 100% beginning 2 weeks after vaccination. A booster dose was administered to most vaccinees 6, 12, or 18 months after the primary dose. The effectiveness of VAQTA Paediatric for use in this community has been demonstrated by the fact that after 9 years, since the trial ended, there has been no case of hepatitis A disease in any vaccinee.

Persistence of immunologic memory was demonstrated with an anamnestic antibody response to a booster dose given 6 to 18 months after the primary dose in children (≥2 years of age) and adolescents. To date, no cases of clinically confirmed hepatitis A disease ≥50 days after vaccination have occurred in these vaccinees from the Monroe Efficacy Study monitored for up to 9 years.

Immunogenicity Studies in Children 12 through 23 Months of Age

In three combined clinical studies that assessed immunogenicity, 1022 initially seronegative subjects received 2 doses of VAQTA Paediatric alone or concomitantly with other vaccines (combined diphtheria toxoid-tetanus toxoid-acellular pertussis and/or Haemophilus influenzae b and/or combined measles-mumps-rubella-varicella and/or combined measles-mumps-rubella and/or varicella and/or pneumococcal 7-valent conjugate vaccine). Seroconversion was achieved in 99.9% of initially seronegative subjects. No significant differences were observed when vaccines were given individually or concomitantly.

Use in Children With Maternal Antibody to Hepatitis A

In a concomitant use study, children received VAQTA Paediatric (25U) at TILDE OPERATOR (8764)12 months and TILDE OPERATOR (8764)18 months of age with or without other paediatric vaccines. After each dose of VAQTA Paediatric (25U), the hepatitis A antibody titres were comparable between children who were initially seropositive to hepatitis A and children who were initially seronegative to hepatitis A. These data suggest that maternal antibody to hepatitis A in children TILDE OPERATOR (8764)12 months of age does not affect the immune response to VAQTA Paediatric.

Antibody Persistence

In studies of healthy children (≥2 years of age) and adolescents who received an initial 25U dose of VAQTA Paediatric at Day 0 and a subsequent 25U dose 6 to 18 months later, the hepatitis A antibody response to date has been shown to persist for at least 10 years. The geometric mean titres (GMTs) tend to decline over time. The GMTs declined over the first 5 to 6 years, but appeared to plateau through 10 years.

Data available from long-term studies up to 10 years on the persistence of HAV antibodies after 2 doses of VAQTA in healthy, immunocompetent subjects up to 41 years of age allows prediction that based on mathematical modeling at least 99% of subjects will remain seropositive (≥10 mlU anti-HAV/mL) at least 25 years after vaccination.

Based on this analysis, an additional vaccination following complete primary immunisation with 2 doses appears to be unnecessary. However, decisions regarding additional vaccination should be based on risk-benefit for the individual.

Post-marketing Safety Study

In a post-marketing safety study, conducted at a large health maintenance organisation in the United States, a total of 12,523 individuals 2 through 17 years of age received 1 or 2 doses of VAQTA Paediatric. Safety was monitored by reviewing medical records that tracked emergency room and outpatient visits, hospitalisations and deaths. There was no serious, vaccine-related, adverse event identified among the 12,523 individuals in this study. There was no nonserious, vaccine-related, adverse event resulting in outpatient visits. There was no vaccine-related, adverse event identified that had not been reported in earlier clinical trials with VAQTA Paediatric.

5.2 Pharmacokinetic properties

Since VAQTA Paediatric is a vaccine, pharmacokinetic studies were not performed.

5.3 Preclinical safety data

Preclinical safety revealed no specific hazard for humans.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium borate

Sodium chloride

Water for injections

For adjuvant see section 2. Qualitative and Quantitative Composition

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

3 Years.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

DO NOT FREEZE since freezing destroys potency.

6.5 Nature and contents of container

0.5 mL of suspension in pre-filled syringe (Type I glass) with a plunger-stopper (chlorobutyl isoprene blend).

0.5 mL of suspension in pre-filled syringe (Type I glass) with a plunger-stopper (chlorobutyl isoprene blend), without needle, with a tip-cap (chlorobutyl isoprene blend), with 0, 1 or 2 separate needles.

0.5 mL of suspension in vial (Type I glass) with a grey rubber stopper (chlorobutyl isoprene blend).

Not all pack sizes and presentations may be marketed.

6.6 Special precautions for disposal and other handling

The vaccine should be used as supplied; no reconstitution is necessary.

Shake well immediately before use. Thorough agitation is necessary to maintain suspension of the vaccine. For syringe without attached needle, hold the syringe barrel and attach the needle by twisting in clockwise direction until the needle fits securely on the syringe.

Parenteral drug products should be inspected visually for extraneous particulate matter and discolouration prior to administration. After thorough agitation, VAQTA Paediatric is a slightly opaque white suspension.

It is important to use a separate sterile syringe and needle for each individual to prevent transmission of infections from one person to another.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Sanofi Pasteur MSD Limited

Mallards Reach

Bridge Avenue

Maidenhead

Berkshire

SL6 1QP

8. Marketing authorisation number(s)

PL 6745/0064

9. Date of first authorisation/renewal of the authorisation

15th August 1996

10. Date of revision of the text

September 2013

11. Legal category

POM

Company contact details

Sanofi Pasteur MSD Limited

Company image
Address

Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP

Fax

+44 (0)1628 671 722

Medical Information e-mail
Telephone

+44 (0)1628 785 291

Medical Information Direct Line

+44 (0)1628 587 693

Medical Information Fax

+44 (0)1628 635 072

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

hepatitis a vaccine, purified inactivated, for paediatrics and adolescents

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.